Ketamine Research and Policy Updates
News and research summaries focused on what changes in evidence, regulation, access, and clinical practice may mean for ketamine patients and providers.
What belongs here
Current research, policy, FDA, DEA, trial, and access updates with patient-facing context and links to primary sources when available.
What to read next
Use news articles for context, then move to the evergreen guide or safety hub for durable treatment planning information.
Contact Ketamine Troche
Send corrections, provider questions, or advertising inquiries.
Featured
3 articlesExpert Insights: Key Ketamine Patient Considerations
Dr. Benjamin Brody highlights critical patient considerations for ketamine treatment at ASCP 2026, with key implications for troche therapy protocols.
Boston Clinics Spotlight Ketamine's Mental Health Role
Boston-area clinics are spotlighting ketamine for depression and anxiety. Here's what their approach means for patients using at-home ketamine troches.
TMS vs. Ketamine: What TRD Patients Should Know
Medical Daily covers when to try ketamine or TMS for treatment-resistant depression. Here's what it means for patients weighing ketamine troches.
Expert Insights: Key Ketamine Patient Considerations
Dr. Benjamin Brody highlights critical patient considerations for ketamine treatment at ASCP 2026, with key implications for troche therapy protocols.
Boston Clinics Spotlight Ketamine's Mental Health Role
Boston-area clinics are spotlighting ketamine for depression and anxiety. Here's what their approach means for patients using at-home ketamine troches.
TMS vs. Ketamine: What TRD Patients Should Know
Medical Daily covers when to try ketamine or TMS for treatment-resistant depression. Here's what it means for patients weighing ketamine troches.
IV Ketamine in the News: What Troche Users Should Know
A FOX 4 Kansas City segment spotlights IV ketamine therapy. Here's what the growing media attention means for ketamine troche patients and at-home access.
Ketamine & Workers' Comp: What Alabama's Rules Mean
Alabama workers' comp cases are testing ketamine therapy coverage standards. Here's what this legal shift means for troche access and reimbursement in 2026.
Esketamine Clinic Protocols: What Troche Patients Should Know
New esketamine clinic-protocol guidance shows why sublingual ketamine troches stay a flexible, accessible alternative for many treatment-resistant patients.
NMDA Side Effects: What the Data Means for Troche Users
New research on NMDA antagonist side effects and discontinuation rates offers practical guidance for ketamine troche patients managing treatment-resistant depression.
Ketamine Dropout Rates: The Case for Troche Optimization
New clinical data on NMDA antagonist side effects and dropout rates reveals why troche dosing flexibility may improve long-term treatment adherence.
Trump EO Could Reshape Ketamine Troche Access in 2026
President Trump's 2026 executive order on psychedelic research signals a regulatory shift that could affect compounded ketamine troche access and prescribing.
Ketamine Dropout Rates: Why Delivery Format Changes Everything
New clinical data on NMDA antagonist side effects and dropout rates shows why ketamine troche delivery may offer a meaningful tolerability advantage.
Side Effects & Stopping Rates: What NMDA Data Means
New data on NMDA antagonist side effects and discontinuation rates has direct implications for ketamine troche patients managing treatment-resistant depression.
FDA Review of Preservative-Free Ketamine Advances
NRx Pharmaceuticals reports progress on FDA review of its preservative-free ketamine application. Here's what it could mean for troche access and compounding.
Ketamine Side Effects: What New Data Means for Troches
New 2026 NMDA-antagonist data on troche side effects and discontinuation rates: how ketamine troches compare on safety and tolerability vs other formats.
NRx's FDA Push for Preservative-Free Ketamine Explained
NRx Pharmaceuticals reports FDA progress on a preservative-free ketamine application. Here's what it means for troche access, compounding, and home dosing.
NMDA Antagonist Side Effects: What Troche Users Should Know
New research compares side effect profiles and dropout rates across NMDA antagonists. Here's what it means for ketamine troche patients in 2026.
BXCL501 PTSD Trial: What It Means for Ketamine Users
A new DoD-backed BXCL501 trial targets acute stress reactions and PTSD prevention. Here's what ketamine troche patients should know.
NMDA Antagonist Side Effects: What Troche Users Need to Know
New clinical guidance on NMDA antagonist side effects and discontinuation rates has direct implications for ketamine troche patients. Here's what it means for your treatment.
Glutamate Pathway Treatments Reshape TRD Care in 2026
New research highlights glutamate-targeting treatments for TRD, including esketamine and ketamine troches. Here's what it means for your care plan.
NMDA Side Effects: What Troche Users Need to Know
New clinical data on NMDA receptor antagonist side effects and dropout rates—and what it means for ketamine troche dosing and monitoring routines.
Insurance Gaps Push Patients to Ketamine Access Funds
Most insurers still deny ketamine coverage for depression. Learn how patient assistance programs are bridging the gap and what it means for troche access.
Esketamine vs. Troches: What TRD Patients Should Know
A new clinical review on esketamine for TRD highlights access barriers and patient preferences — here's what it means for ketamine troche therapy.
Esketamine TRD Access Gaps Open Doors for Troches
New clinician data on esketamine for TRD reveals access barriers that make compounded ketamine troches a practical frontline option for many patients.
France Approves IV Ketamine for Suicidal Crisis: What It Means
France has approved IV ketamine for acute suicidal crises. Here's what this global shift means for ketamine troche patients and at-home treatment access in the U.S.
Glutamate Pathways Are Reshaping TRD Treatment
A 2026 review highlights how glutamate-targeting drugs like esketamine and ketamine troches are redefining treatment-resistant depression care.
Glutamate Pathway Treatments Reshape TRD Care
New research highlights glutamate-based treatments for treatment-resistant depression. Here's what it means for ketamine troche patients in 2026.
BXCL501 Enters Phase 2a for Acute Stress and PTSD Prevention
BioXcel's sublingual dexmedetomidine enters a DoD-backed Phase 2a trial for acute stress reactions — what it means for the trauma treatment landscape.